london euretina
retina race

Application of an aflibercept in treatment a wet form of an age-related macular degeneration

Session Details

Session Title: AMD II

Session Date/Time: Friday 18/09/2015 | 14:30-16:00

Paper Time: 15:42

Venue: Calliope.

First Author: : G.Zhurgumbaeyva KAZAKHSTAN

Co Author(s): :    T. Botabelkova   G. Zhurgumbaeva   N. Aldasheva   N. Aldasheva   L. Muraveva  

Abstract Details

PURPOSE:To estimate efficiency of intravitreal injections of aflibercept in patients with wet AMD.

Setting:

Age-related macular degeneration (AMD) is the main reason for a blindness in the developed countries. Aflibertsept 'Eylea', a recombinant hybrid protein that inhibiting all isoforms of VEGF-A, is approved for the treatment of the wet form of AMD.

Methods:

Material and methods. Under supervision there were 18 patients (18 eyes) with the wet form of AMD. The median age was 62,7 ± 5,7 years. maximum correcting visual acuity (MCVA) before injection ranged from 0.04 to 0.1 (average of 0,06 ± 0,02). Retinal thickness at the center according to the OST from 303 to 509 microns (average 419 ± 68mk). All patients received 3 loading injections of 'Eylea' with a difference in a month by a standard method. In all cases in the postoperative period for 2 days appointed by carbonic anhydrase inhibitors in the instillation of 5 days - a combination of antibacterial and anti-inflammatory drugs. Monitoring between injections was not performed.

Results:

Complications of inflammatory character and a postoperative ocular hypertension wasn't observed. All patients for the first days after an injection subjectively noted reduction of distortion of the image, contrast increase. MCVA after 3 injections raised in all cases and averaged 0,3 ± 0,09 (0.1 to 0.65) The thickness of the retina at the center according to OST decreased in all patients, averaging 290 ± 46 microns ( from 227 to 368 microns).

Conclusions:

Intravitreal injection of 'Eylea' is an effective in the treatment of the wet form of AMD, promoting reduction of thickness of a retina in the center by 1,4 times and raises MCVA by 5 times.

Back to previous
EURETINA, Temple House, Temple Road, Blackrock, Co Dublin. | Phone: 00353 1 2100092 | Fax: 00353 1 2091112 | Email: euretina@euretina.org

Privacy policyHotel Terms and Conditions Cancellation policy